Biofrontera

Biofrontera Financing Cash Flow

The Net Financing Cash Flow of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -452,000.00 EUR. In the previous year, Net Financing Cash Flow was 2.79 M EUR — a change of -116.18% (lower).

Financing Cash Flow

-452,000.00EUR

YoY

-116.18%

Last updated:

Net Financing Cash Flow of Biofrontera is 2025 -452,000.00 EUR. Net Financing Cash Flow of Biofrontera was 2024 2.79 M EUR. It decreases by -116.18% lower compared to the previous year.

The Biofrontera Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
22.27 M EUR
Jan 1, 2019
3.46 M EUR
Jan 1, 2020
5.95 M EUR
Jan 1, 2021
2.18 M EUR
Jan 1, 2022
4.34 M EUR
Jan 1, 2023
-467,000.00 EUR
Jan 1, 2024
2.79 M EUR
Jan 1, 2025
-452,000.00 EUR
The Biofrontera Financing Cash Flow history
YEARFinancing Cash FlowYoY
-452,000.00EUR-116.18%
2.79 MEUR-698.07%
-467,000.00EUR-110.75%
4.34 MEUR+99.08%
2.18 MEUR-63.32%
5.95 MEUR+72.16%
3.46 MEUR-84.49%
22.27 MEUR+135.68%
9.45 MEUR-57.74%
22.36 MEUR+334.20%
5.15 MEUR-61.64%
13.42 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Net Financing Cash Flow of Biofrontera is -452,000.00 EUR in 2025.

Net Financing Cash Flow of Biofrontera changed from 2.79 M EUR to -452,000.00 EUR, representing a -116.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biofrontera

All Key Metrics — Biofrontera